Press Release EU ZA

Bloomwell Group Closes Multi-Million Euro Growth Capital Round With Leading US Venture Capital Investors

Published

2 years ago

February 10, 2023

admin

FRANKFURT-based medical cannabis holding company Bloomwell Group (“Bloomwell,” “Bloomwell Group,” or the “Company”) has closed a significant multi-million Euro funding round led by Artemis Growth Partners (“Artemis”), a premier American investment fund specializing in impact investing across global cannabis markets.

Also participating in this latest funding round are existing seed investor, Measure 8 Venture Partners (“Measure 8”), along with a German family office investing in medical cannabis for the first time, and award-winning, Germany-born film actor Moritz Bleibtreu. Existing Bloomwell investors committed new capital as reinvestment in support of the offering. The terms of the multi-million Euro financing are undisclosed.

As part of the transaction, Artemis co-founder and managing member William Muecke has joined the Company’s advisory board and will serve alongside Bloomwell’s current board representatives. Mr. Muecke was previously the global co-head of healthcare services in the healthcare investment banking group at Goldman Sachs and Co. With over 30 years of experience in global financial markets, Mr. Muecke is an expert in corporate finance, mergers and acquisitions, and private equity investing.

The large size of the investment and the marquee name recognition of the institutional capital now joining Bloomwell’s investor group is a noteworthy endorsement of Bloomwell’s success to date, as well as a statement of confidence in Bloomwell’s management team, who has guided the Company to its leading market position in German medical cannabis.

This latest investment provides Bloomwell with a fully-funded business model and positions the Company to continue to both increase current market share as well as prepare the business for the expected upcoming federal legalization of adult-use cannabis in Germany.

“We are pleased to be one of the very few select businesses who have been able to close funding in what has been a very difficult period in the private capital markets. Indeed, we are humbled to not only have the continued support of our existing investors but also to have been able to attract new lead capital from such a highly reputable group as Artemis, which is a statement of confidence and vision that we accept and embrace,” said Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group. “At Bloomwell, our patient-first approach and our unwavering quest for quality and service have guided us from inception to the leadership position we hold today in German medical cannabis. We believe it is this unrelenting spirit of quality and success that has attracted the world’s best cannabis investors to our company, and we are pleased to have a fully funded business with significant opportunity and growth ahead of us.”

“Germany is the most important European market for medical cannabis, and the country will become the world’s largest Federally-legal domestic cannabis market when adult-use cannabis sales begin. We are excited to join Nik and the team as investors and supporters of Bloomwell’s continued growth and success, and we believe that Bloomwell is the best-positioned independent German medical cannabis business operating today. We believe the leadership that Bloomwell has shown in the German market will translate into an expanding growth story across Europe, and we enthusiastically join the Company’s board to help guide the Company on its path forward. Among all global markets, Europe is the future for patient service, adult use access, and stigma-free acceptance of cannabis, and Germany is the engine powering the train in terms of responsible regulation, durable codification, and profitable growth in legal cannabis.” said Mr. Muecke.

Alongside Artemis, a leading German family office has taken a meaningful ownership stake in Bloomwell and will bring its industrial non-cannabis network, and its operational and financial expertise to enhance and accelerate Bloomwell’s growth.

In addition, Moritz Bleibtreu is investing in the round and will also work alongside Bloomwell Group to advocate for the continued de-stigmatization of medicinal cannabis.

“Although the potential of the cannabis plant is far from being fully understood, there is now sufficient evidence to justify legalization and expanding consumer access. The cannabis plant can help many people advance their wellness goals. We should stop pigeonholing a plant on the basis of decades of antiquated prejudices,” said Mr. Bleibtreu, who is one of Germany’s most successful actors. Mr. Bleibtreu is a well-known German actor and public personality who achieved fame for his roles in classic movies such as Run Lola Run, The Experiment, Lammbock – Alles in Handarbeit, Elementarteilchen and Der Baader Meinhof Komplex. Mr. Bleibtreu received a Germany Television Award (The Deutscher Fernsehpreis) last year for his performance in the series Faking Hitler.

“We are very pleased that Moritz Bleibtreu, an accomplished actor with an international reputation, is joining our mission and offering financial support as we work to end the decades-long stigma of the cannabis plant and cannabis consumers. We can only succeed in changing public perceptions if we involve courageous personalities in the public discourse who will help to educate, promote the plant’s potential benefits, and strengthen the spirit of the cannabis community,” added Mr. Kouparanis.

Source https://businesscann.com/bloomwell-group-closes-multi-million-euro-growth-capital-round-with-leading-us-venture-capital-investors-and-award-winning-actor-moritz-bleibtreu/

Source link

Press Release

Aurora Cannabis and Vectura Fertin Pharma announce commercial collaboration

Published

1 month ago

August 4, 2024

admin

Aurora Cannabis Inc., a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, have announced that Aurora has entered into a commercial collaboration with Cogent International Manufacturing Ltd., a wholly-owned subsidiary of Vectura Fertin Pharma.

Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora’s Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis.

Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialisation of other Vectura Fertin Pharmamedical cannabis products in Canada.

“We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma’s new CBD lozenge,” said Miguel Martin, CEO for Aurora. “As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of healthcare options made available to Canadians.”

Michael Kunst, CEO for Vectura Fertin Pharma, said: “At Vectura Fertin Pharma, we are committed to building a pipeline of innovation, based on scientific rigor, to improve unmet medical and health needs. We are delighted to be working with the Aurora team who share our high standards for safety and quality, and our strong focus on improving people’s lives.

“Through this strategic collaboration, the Aurora platform will enable us to bring our new CBD lozenge, as prescribed by a healthcare professional, to the largest patient base in Canada, and to both study its impact and validate the product proposition through the generation of real-world patient data.”

The agreement between Aurora and Cogent is expected to have an initial term of 24 months, with a target of launching CBD containing products on Aurora’s Canadian medical cannabis marketplace, starting with a CBD lozenge.

The products will be manufactured, packaged and labelled by Cogent for sale and distribution by Aurora through its leading direct-to-patient e-commerce sales channel, requiring minimal additional capital investment by Aurora. The expected launch of the first SKU in market is targeted for later in 2024.

https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/aurora-cannabis-and-vectura-fertin-pharma-announce-commercial-collaboration/

Source link

Press Release

Lyphe and Gro-Vida Announce Partnership

Published

3 months ago

June 15, 2024

admin

Lyphe Clinic has announced a partnership with Gro-Vida, a licensed medical cannabis cultivar. This collaboration marks a significant step forward in advancing patient care and access to high-quality medical cannabis products within the UK.

By forming a strategic partnership with Gro-Vida, Lyphe Clinic aims to further enhance its commitment to providing superior care and uninterrupted access to medical cannabis treatments for its patients.

Sophie Gamwell, Managing Director at Lyphe Clinic, expressed her enthusiasm about the partnership, stating: “We are delighted to join hands with Gro-Vida to ensure seamless access to medical cannabis for our patients. Guaranteeing a continuous and reliable supply of medication is paramount for their well-being, and this partnership enables us to fulfil that commitment.”

Mallory Bodnar, Managing Director at Gro-Vida, commented:“Our partnership with Lyphe Clinic represents a significant step forward in our shared commitment to enhancing patient well-being. We are thrilled about this collaboration, which embodies our joint dedication to elevating standards of care. Together, we are ensuring that patients have access to high-quality, consistent medical cannabis.”

Through this partnership, Lyphe Clinic patients will benefit from a streamlined medical cannabis supply chain, ensuring consistent access to their prescribed medication. Additionally, the collaboration will empower Lyphe Clinic to exercise greater control over the quality and cost of the medical cannabis provided to its patients, ultimately enhancing the overall patient experience.

Source link

Press Release

Akanda Corp. Announces Closing of the Sale of RPK to Somai

Published

5 months ago

April 14, 2024

admin

London, United Kingdom–(Newsfile Corp. – April 11, 2024) – On April 1, 2024, Akanda Corp. (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, completed the transaction with SOMAÍ Pharmaceuticals Ltd. (the “Buyer”) for the sale of RPK, its indirect wholly-owned Portuguese subsidiary.

Pursuant to the provisions set forth in the definitive share purchase agreement, the cash purchase price is Two Million United States Dollars (USD $2,000,000). In addition SOMAÍ is assuming up to One Millions Euros of current liabilities and RPK’s debt with the senior secured lender Bank, Caixa Agricola. In total the Buyer is assuming approximately 4,000,000 Euros of debt. In accordance with the terms of the proposed transaction, a deposit amounting to Five Hundred Thousand United States Dollars (USD $500,000) was released from a joint escrow account and the remainder of the purchase price was paid directly to the Company.

Akanda Corp. is now in a stronger financial position and will continue to strengthen its presence in the global cannabis market through its wholly-owned United Kingdom (UK) subsidiary, Canmart. Canmart is a licensed importer and distributor of Cannabis-Based Products for Medicinal use (CBPMs) in the UK. and provides third party and specialist import and distribution services for Schedule 2 products including CBPM’s. Canmart continues to work further with premium product suppliers to bring safe, effective and required products to market that patients demand, and working with existing and new clinical cannabis operations in the UK to provide third party products. Beyond its operations in the UK, Akanda is also developing the Gabriola Green Project in British Columbia, Canada. This farming property is set to host facilities for the production of tetrahydrocannabinol (THC) and cannabinoid (CBD) products, reflecting the Company’s commitment to expanding its footprint and advancing its projects across both Europe and North America. The Company has initiated the regulatory framework to begin CBD cultivation with a future outlook towards THC.

Interim CEO and Executive Director, Katie Field commented, “Akanda is in a strong position to execute a new sustainable strategic direction. The company is in a better cash position and has eliminated most of its debt. We are looking forward to the Company’s anticipated growth.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

Source link